HTL Biotechnology

Sector Healthcare
Location Paris
Date acquired 2018
Transaction size Not disclosed

A leading producer of high-quality hyaluronic acid


In November 2021, HTL was sold to a consortium of investors led by Montagu for an undisclosed sum.

To learn more about the company, click here.

Formed in 1992, HTL is based in Fougères (Ille-et-Vilaine, Brittany) and specialises in the manufacture and purification of Hyaluronic acid (HA), a high-growth specialist pharmaceutical ingredient used in numerous pharma applications. HTL has since diversified into research and development covering other biological polymers for the pharmaceutical and medical fields.

HTL stands out from the competition because of its ability to obtain HA with an ultra-high molecular weight, which adds stability and effectiveness for injectable products prepared in the fields of ophthalmology, rheumatology, or dermatology. It is also one of the few global manufacturers that can produce a significant volume of pharmaceutical-quality HA. Although headquartered in France, 75% of its revenues are generated from non-domestic customers.

We use strictly necessary cookies to make our site work. Currently the analytics cookies which allow us to collect information about how visitors use our website and help us to improve it; is defaulted to ‘InActive’, if you wish to turn this on you can do so through the Cookie Settings. Please be aware that by blocking some types of cookies it may impact your experience of the site and the services we are able to offer. For more information about any of these cookies and our use of them, or to change your settings at any time, please see Cookie Settings and Cookies Policy.